# Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer

> **NCT02317874** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 43 (actual)

## Conditions studied

- Advanced Malignant Solid Neoplasm
- Metastatic Malignant Solid Neoplasm
- Unresectable Malignant Solid Neoplasm

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Talazoparib

## Key facts

- **NCT ID:** NCT02317874
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-08
- **Primary completion:** 2019-04-01
- **Final completion:** 2022-05-03
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2023-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02317874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02317874, "Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02317874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*